Drug Approval | June 14, 2024
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
There was no observation related to data integrity reported
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
Subscribe To Our Newsletter & Stay Updated
